But Pfizer saw more opportunities and bigger profits for its blockbuster drug, and cast a wider net in the pain department. As a result, in September of 2009 the drug giant paid $2.3 billion to settle criminal and civil charges in the U.S. for the “off-label” marketing of Lyrica and other medications. “Contrary to the approved intended uses, Pfizer marketed Lyrica for the treatment of chronic pain, neuropathic pain (other than DPN and PHN), perioperative pain, and migraine,” stated the lawsuit.
Lyrica (the brand name for Pregabalin) is classified as a miscellaneous analgesic and anticonvulsant, and was approved in 2004 for “the management of neuropathic pain associated with diabetic peripheral neuropathy (DPN) and postherpetic neuralgia (PHN); and use as adjunctive therapy for adult patients with partial onset seizures. (Neuropathic pain is chronic pain that arises from damage to sensory nerves, such as pain arising from trapped or compressed nerves, drug-induced nerve damage, phantom limb syndrome following limb amputation, andfibromyalgia.)
Also in 2009--a pivotal year for Lyrica--the FDA issued a warning to physicians, advising they recommend that pregnant patients taking Lyrica enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry. And to patients: “they should be encouraged to enroll in the NAAED Pregnancy Registry if they become pregnant.” In other words, The FDA warning label for Lyrica does not specifically warn pregnant women not to take the drug. But it does caution them to consult with a doctor if they are pregnant or plan to become pregnant.
READ MORE LYRICA BIRTH DEFECT LEGAL NEWS
Lyrica remains one of Pfizer’s top selling drugs, generating $5.1 billion in revenue in 2014 – the year when Pfizer’s patent on Lyrica for epilepsy and anxiety expired. But its secondary patent for pain is good until July of 2017.